Gene-based therapy in prostate cancer

Prostate cancer is one of the commonest causes of illness and death from cancer. Radical prostatectomy, radiotherapy, and hormonal therapy are the main conventional treatments. However, gene therapy is emerging as a promising adjuvant to conventional strategies, and several clinical trials are in pr...

Full description

Saved in:
Bibliographic Details
Published in:The lancet oncology 2004-08, Vol.5 (8), p.469-479
Main Authors: Foley, Ruth, Lawler, Mark, Hollywood, Donal
Format: Article
Language:English
Subjects:
Androgens
Apoptosis
Cancer therapies
Cell growth
Clinical trials
Cytokines
Drug withdrawal
Enzymes
Gene expression
Gene Expression Regulation, Neoplastic
Gene therapy
Gene Transfer Techniques
Genetic engineering
Genetic Therapy
Growth factors
Herpes viruses
Humans
Immune system
Kinases
Male
Promoter Regions, Genetic
Prostate cancer
Prostatic Neoplasms - genetics
Prostatic Neoplasms - therapy
Proteins
Radiation therapy
Tumors
Vectors (Biology)
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Prostate cancer is one of the commonest causes of illness and death from cancer. Radical prostatectomy, radiotherapy, and hormonal therapy are the main conventional treatments. However, gene therapy is emerging as a promising adjuvant to conventional strategies, and several clinical trials are in progress Here, we outline several approaches to gene therapy for prostate cancer that have been investigated. Methods of gene delivery are described, particularly those that have commonly been used in research on prostate cancer. We discuss efforts to achieve tissue-specific gene delivery, focusing on the use of tissue-specific gene promoters Finally, the present use of gene therapy for prostate cancer is evaluated. The ability to deliver gene-therapy vectors directly to prostate tissue, and to regulate gene expression in a tissue-specific manner, offers promise for the use of gene therapy in prostate cancer.
ISSN:1470-2045
1474-5488
DOI:10.1016/S1470-2045(04)01525-6